Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Other financing activities (2018 - 2025)

CorMedix's Other financing activities history spans 7 years, with the latest figure at $5.4 million for Q4 2025.

  • For Q4 2025, Other financing activities changed N/A year-over-year to $5.4 million; the TTM value through Dec 2025 reached $9.8 million, changed N/A, while the annual FY2025 figure was $5.7 million, N/A changed from the prior year.
  • Other financing activities for Q4 2025 was $5.4 million at CorMedix, up from $1.1 million in the prior quarter.
  • Across five years, Other financing activities topped out at $5.4 million in Q4 2025 and bottomed at $1.1 million in Q2 2023.
  • The 3-year median for Other financing activities is $1.1 million (2022), against an average of $2.2 million.
  • The largest YoY upside for Other financing activities was 94.71% in 2023 against a maximum downside of 1.52% in 2023.
  • A 3-year view of Other financing activities shows it stood at $1.1 million in 2022, then decreased by 1.52% to $1.1 million in 2023, then surged by 415.15% to $5.4 million in 2025.
  • Per Business Quant, the three most recent readings for CRMD's Other financing activities are $5.4 million (Q4 2025), $1.1 million (Q2 2023), and $2.2 million (Q1 2023).